Evaxion Biotech A/S

NasdaqCM:EVAX Stock Report

Market Cap: US$4.3m

Evaxion Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EVAX?
Owner TypeNumber of SharesOwnership Percentage
Institutions13,7711.17%
VC/PE Firms108,4579.24%
Hedge Funds111,0559.47%
Individual Insiders219,28018.7%
General Public720,64861.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.7%.

Top Shareholders

Top 20 shareholders own 38.57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.47%
Armistice Capital LLC
111,055US$404.2k41.7%0.01%
9.24%
Merck Global Health Innovation Fund, LLC
108,457US$394.8k0%100.0%
7.38%
Niels Moeller
86,580US$315.2k1.83%no data
7.31%
Andreas Mattsson
85,713US$312.0k2.1%no data
1.39%
Marianne Sogaard
16,340US$59.5k157%no data
1.25%
Christian Kanstrup
14,705US$53.5k14.3%no data
0.74%
Invst, LLC
8,640US$31.4k-20%no data
0.69%
Roberto Pineda
8,043US$29.3k0%no data
0.36%
Steven Projan
4,222US$15.4k0%no data
0.25%
Citadel Advisors LLC
2,965US$10.8k0%no data
0.13%
Lars Holtug
1,470US$5.4k0%no data
0.083%
Beacon Capital Management, LLC
972US$3.5k0%no data
0.063%
Lars Wegner
737US$2.7k0%no data
0.063%
Birgitte Rono
735US$2.7k0%no data
0.063%
Jesper Nissen
735US$2.7k0%no data
0.058%
Geode Capital Management, LLC
677US$2.5k1.2%no data
0.026%
BlackRock, Inc.
302US$1.1k0%no data
0.013%
JPMorgan Chase & Co, Brokerage and Securities Investments
156US$568.0-64.2%no data
0.0049%
Rhumbline Advisers Ltd Partnership
58US$211.00%no data
0.00009%
SCBT Financial Corp., Asset Management Arm
1US$3.80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 22:36
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evaxion Biotech A/S is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Ahu DemirLadenburg Thalmann & Company
Thomas FlatenLake Street Capital Markets, LLC